| |  Online-Ressource |
|---|
| Verfasst von: | Zschäbitz, Stefanie [VerfasserIn]  |
|---|
| | Grüllich, Carsten [VerfasserIn] |
|---|
| Titel: | Lenvantinib |
|---|
| Titelzusatz: | a tyrosine kinase inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα, KIT and RET |
|---|
| Verf.angabe: | Stefanie Zschäbitz, Carsten Grüllich |
|---|
| E-Jahr: | 2018 |
|---|
| Jahr: | 02 August 2018 |
|---|
| Umfang: | 12 S. |
|---|
| Fussnoten: | Gesehen am 06.04.2020 |
|---|
| Titel Quelle: | Enthalten in: Small molecules in oncology |
|---|
| Ausgabe Quelle: | Third edition |
|---|
| Ort Quelle: | Cham, Switzerland : Springer, 2018 |
|---|
| Jahr Quelle: | 2018 |
|---|
| Band/Heft Quelle: | (2018), Seite 187-198 |
|---|
| ISBN Quelle: | 978-3-319-91442-8 |
|---|
| Abstract: | Lenvatinib is an oral receptor tyrosine kinase inhibitor (TKI) with activity against vascular endothelial growth factor (VEGF) receptors 1-3, fibroblast growth factor receptors (FGFR) 1-4, platelet-derived growth factor receptor-alpha (PDGFRα), and RET and KIT proto-oncogenes. Lenvatinib is approved for the treatment of radioiodine-refractory differentiated thyroid cancer and in combination with everolimus for the treatment of advanced renal cell carcinoma following anti-VEGF treatment. In hepatocellular carcinoma lenvatinib was non inferior to sorafenib in first line with an improved progression-free survival and approval in this indication is expected. Lenvatinib is currently investigated for further indications as single agent and in combinations. Side effects include typical TKI induced toxicities such as hypertension, diarrhea, hypothyroidism, and fatigue. |
|---|
| DOI: | doi:10.1007/978-3-319-91442-8_13 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Verlag: https://link.springer.com/chapter/10.1007%2F978-3-319-91442-8_13 |
|---|
| | Verlag: https://europepmc.org/article/med/30069768 |
|---|
| | DOI: https://doi.org/10.1007/978-3-319-91442-8_13 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Animals |
|---|
| | Antineoplastic Agents |
|---|
| | Differntiated thyroid cancer |
|---|
| | Hepatocellular carcinoma |
|---|
| | Humans |
|---|
| | Lenvantinib |
|---|
| | Neoplasms |
|---|
| | Phenylurea Compounds |
|---|
| | Protein Kinase Inhibitors |
|---|
| | Proto-Oncogene Proteins c-kit |
|---|
| | Proto-Oncogene Proteins c-ret |
|---|
| | Quinolines |
|---|
| | Receptor Protein-Tyrosine Kinases |
|---|
| | Receptor, Platelet-Derived Growth Factor alpha |
|---|
| | Receptors, Vascular Endothelial Growth Factor |
|---|
| | Renal cell carcinoma |
|---|
| K10plus-PPN: | 1694063526 |
|---|
| Verknüpfungen: | → Sammelwerk |
|---|
Lenvantinib / Zschäbitz, Stefanie [VerfasserIn]; 02 August 2018 (Online-Ressource)
